|Bid||37.50 x 200|
|Ask||39.50 x 100|
|Day's Range||34.27 - 38.79|
|52 Week Range||26.51 - 38.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.33|
Avrobio Inc (NASDAQ: AVRO ), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 million ...
AVROBIO, Inc. (AVRO), a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene therapies to treat rare diseases following a single dose, today announced the appointment of Phillip B. Donenberg to its Board of Directors. Mr. Donenberg brings more than 23 years of leadership expertise in finance, mergers and acquisitions (M&A) and operations focused in the pharmaceutical and healthcare industries.
CAMBRIDGE, Mass., June 25, 2018-- AVROBIO, Inc., a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases ...
Five heavily funded biotech startups could soon join the parade of drugmakers marching onto the public markets.
Five more venture-backed biotechnology companies were set to begin public trading Thursday, after each priced within or above its expected range.
Inc. went public Wednesday during what should be one of the busiest weeks for biomedical IPOs in recent memory. Nine U.S. venture-backed biotechs had their debuts in the first quarter, according to VentureSource. Enthusiasm for biotech is fueling much of the activity.
CAMBRIDGE, Mass., June 20, 2018-- AVROBIO, Inc., a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases ...
This week, there are a whopping eight biotech companies going public. Biotechnology isn’t an easy sector to grasp — it takes dedication to understand investment thesis, beginning the journey from drug development and ending at the drugstore. When it comes to investing in biotech stocks, the question is not just how well is this business run but whether their products fulfill a need in a growing industry … for biotechs, this can get complicated.